ATE449787T1 - Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden - Google Patents
Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurdenInfo
- Publication number
- ATE449787T1 ATE449787T1 AT99970091T AT99970091T ATE449787T1 AT E449787 T1 ATE449787 T1 AT E449787T1 AT 99970091 T AT99970091 T AT 99970091T AT 99970091 T AT99970091 T AT 99970091T AT E449787 T1 ATE449787 T1 AT E449787T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- mage
- ctl clones
- isolated
- ctl
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 241000607734 Yersinia <bacteria> Species 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/165,863 US6407063B1 (en) | 1998-10-02 | 1998-10-02 | Tumor antigens and CTL clones isolated by a novel procedure |
US09/289,350 US6531451B1 (en) | 1998-10-02 | 1999-04-09 | Tumor antigens and CTL clones isolated by a novel procedure |
PCT/IB1999/001664 WO2000020445A2 (en) | 1998-10-02 | 1999-09-15 | Tumor antigens and ctl clones isolated by a novel procedure |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE449787T1 true ATE449787T1 (de) | 2009-12-15 |
Family
ID=22600796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99970091T ATE449787T1 (de) | 1998-10-02 | 1999-09-15 | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden |
Country Status (4)
Country | Link |
---|---|
US (2) | US6407063B1 (de) |
JP (1) | JP4722289B2 (de) |
AT (1) | ATE449787T1 (de) |
DE (1) | DE69941719D1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69533295T3 (de) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
JP2003512829A (ja) | 1999-10-22 | 2003-04-08 | アヴェンティス パストゥール リミテッド | 改変型gp100およびその使用 |
EP1741782B1 (de) * | 2000-05-10 | 2011-06-22 | Sanofi Pasteur Limited | Durch Mage Minigene kodierte immunogene Polypeptide und ihre Verwendungen |
WO2005035773A2 (en) * | 2003-10-08 | 2005-04-21 | Sanofi Pasteur, Inc. | Modified cea /b7 vector |
PT1496939E (pt) * | 2002-04-09 | 2007-11-22 | Sanofi Pasteur Ltd | ''ácido nucleico de cea modificado e vectores de expressão'' |
EP1556082A1 (de) * | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Impfstoffe gegen krebs mit hochdosierten zytokinen als adjuvans |
CA2547635C (en) * | 2003-12-12 | 2016-02-09 | Jeffrey Schlom | A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1 |
WO2006088492A2 (en) * | 2004-07-01 | 2006-08-24 | The Regents Of The University Of Califorrnia | High throughput proteomics |
CN101041816B (zh) * | 2006-12-01 | 2010-08-25 | 扬州大学 | 人工抗原递呈细胞及其制备方法 |
US8313894B2 (en) | 2008-07-01 | 2012-11-20 | Genocea Biosciences, Inc. | Antigen screening system |
EP3925972A1 (de) * | 2016-04-08 | 2021-12-22 | Adaptimmune Ltd | T-zell-rezeptoren |
KR20190142767A (ko) | 2017-03-20 | 2019-12-27 | 제노세아 바이오사이언스, 인코퍼레이티드 | 치료 방법 |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
KR20210148106A (ko) | 2019-03-08 | 2021-12-07 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 조절을 위한 cd40l 조성물 및 방법 |
CN113966397A (zh) | 2019-03-08 | 2022-01-21 | 黑曜石疗法公司 | 人碳酸酐酶2组合物和用于可调调节的方法 |
US20200318068A1 (en) * | 2019-04-04 | 2020-10-08 | Immatics US, Inc. | Use of retinoic acid in t-cell manufacturing |
CA3140668A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
US20220267398A1 (en) | 2019-06-12 | 2022-08-25 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
WO2021142376A1 (en) | 2020-01-08 | 2021-07-15 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of transcription |
CN111534546A (zh) * | 2020-05-09 | 2020-08-14 | 赛诺(深圳)生物医药研究有限公司 | 一种具有多等位基因p53编码序列的重组腺病毒的制备方法 |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5925729A (en) * | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
AU4998993A (en) | 1992-08-07 | 1994-03-03 | Epimmune, Inc. | Hla binding peptides and their uses |
US5558995A (en) | 1993-01-22 | 1996-09-24 | Ludwig Institute For Cancer Research | Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof |
US6328971B1 (en) | 1993-01-22 | 2001-12-11 | Ludwig Institute For Cancer Research | MAGE-1 derived nona peptides, and compositions thereof |
JPH09502086A (ja) * | 1993-08-06 | 1997-03-04 | サイテル コーポレイション | 完全mage1遺伝子のクローニング及び特性決定 |
EP0879282B1 (de) * | 1996-01-17 | 2003-07-02 | Imperial College Innovations Limited | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
US6265215B1 (en) | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
US5965535A (en) | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
CA2323632A1 (en) | 1998-03-13 | 1999-09-16 | Epimmune Inc. | Hla-binding peptides and their uses |
-
1998
- 1998-10-02 US US09/165,863 patent/US6407063B1/en not_active Expired - Lifetime
-
1999
- 1999-04-09 US US09/289,350 patent/US6531451B1/en not_active Expired - Lifetime
- 1999-09-15 AT AT99970091T patent/ATE449787T1/de active
- 1999-09-15 JP JP2000574556A patent/JP4722289B2/ja not_active Expired - Fee Related
- 1999-09-15 DE DE69941719T patent/DE69941719D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2003518911A (ja) | 2003-06-17 |
US6531451B1 (en) | 2003-03-11 |
JP4722289B2 (ja) | 2011-07-13 |
DE69941719D1 (de) | 2010-01-07 |
US6407063B1 (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE449787T1 (de) | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden | |
ES2924709T3 (es) | Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer | |
RU2770447C2 (ru) | Способ лечения рака | |
US10968430B2 (en) | Use of specific regulatory T-cells to induce immune tolerance | |
von Boehmer | The selection of the α, β heterodimeric T-cell receptor for antigen | |
Kimura et al. | cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2 (+) cytotoxic T lymphocytes | |
Bozzacco et al. | Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells | |
ES2531142T3 (es) | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden | |
HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
AR018064A1 (es) | Proteina de fusion que consiste en un antigeno asociado a tumores derivado de la familia mage, secuencia de acido nucleico que la codifica, vector que lo comprende, celula huesped que no puede generar un individuo completo transformada con dicho acido nucleico, vacuna que contiene dicha proteina, su | |
EP4253958A3 (de) | Mittel und verfahren zur glykoprofilierung eines proteins | |
BR9809656A (pt) | Composição imunopotencializante | |
DK1257290T3 (da) | Fremgangsmåde til antigen-specifik stimulation af T-lymfocytter med syntetiske peptidbiblioteker | |
NO963918D0 (no) | Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav | |
DK1448229T3 (da) | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr | |
CN112639136A (zh) | 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法 | |
Golstein et al. | Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions | |
DK0570489T3 (da) | Leverstadium-specifikke peptidsekvenser af P.falciparum, der bærer epitoper, som er i stand til at stimulere T-lymfocytter | |
DE602006010934D1 (de) | Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika | |
MX2022003432A (es) | Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada. | |
Bergman et al. | Characterization of H+, K+‐ATPase T cell epitopes in human autoimmune gastritis | |
Levin et al. | Potent activation of human T cells by mRNA encoding constitutively active CD40 | |
WAKSMAN | Overview: Biology of the lymphokines | |
TW200611706A (en) | Cytotoxic t lymphocyte | |
RU2005106841A (ru) | Эпитопы т-клеток в эритропоэтине |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1117679 Country of ref document: EP |